LOS ANGELES, Nov. 26, 2008 (GLOBE NEWSWIRE) -- In an interview Jay Higham, CEO of IntegraMed America, Inc. (Nasdaq:INMD) said, "IntegraMed is cash flow positive based on very visible top line revenue and is poised for growth.
IntegraMed is dominant in two growing U.S. healthcare segments - fertility care & vein care.
INTERVIEW HIGHLIGHTS
"IntegraMed has been profitable the last three years as well as the last four quarters. September quarter revenue was up 30%, the company is selling for book value and has 40% of book value in cash, "according to the interviewer.
The interview is available is available at PrecisionIR/Vcall
http://www.investorcalendar.com/ClientPage.asp?ID=137990
and is based on this interview fact sheet.
http://www.gaskinsco.com/linkto-inmd.shtml
About IntegraMed America
http://www.integramed.com/inmdweb/
Statements contained in this press release that are not based on historical fact, including statements concerning future results, performance, expectations and expansion of IntegraMed are forward-looking statements that may involve a number of risks and uncertainties. Actual results may differ materially from the statements made as a result of various factors, including, but not limited to, the risks associated with IntegraMed's ability to finance future growth; changes in insurance coverage, government laws and regulations regarding health care or managed care contracting; and other risks, including those identified in the company's most recent Form 10-K and in other documents filed by IntegraMed with the U.S. Securities and Exchange Commission. All information in this press release is as of September 30, 2008 and IntegraMed undertakes no duty to update this information.